1) Uli Hacksell took over as CEO on October 15, 2018. 2) Christine Lind took over of Active Biotech, Cerecor Inc., InDex Pharmaceu- ticals AB

neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and Chief Executive Officer, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Chief Executive Officer.

• Teva Pharmaceuticals appointed Kare Shultz as CEO. THIS MONTH'S. 7 apr 2021 Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. Att stämman beslutar Därefter har han varit vd för Cerecor och Medivir. 7 apr 2021 Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande. g. Att stämman Därefter har han varit vd för Cerecor och Medivir.

Uli Hacksell Net Worth The estimated Net Worth of Uli Hacksell is at least $59.6 millier dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0. Exhibit 10.11. EXECUTIVE EMPLOYMENT AGREEMENT. This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 1, 2016 (the “Effective Date”), by and between Uli Hacksell (the “Executive”) and Cerecor Inc., a Delaware corporation (the “Company”).

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. Exhibit 10.11 .

“Because of the predominant hippocampal location of TARP-γ8-dependent AMPA receptors, we believe that the efficacy and side effect profile of CERC-611 may represent an improvement compared to current antiepileptics,” said Uli Hacksell, Ph.D., Cerecor’s CEO, President and Chairman.

Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.

Uli Hacksell Net Worth The estimated Net Worth of Uli Hacksell is at least $59.4 mil dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,400 and over the last 17 years Uli sold CERC stock worth over $0.

Chairman of the Board. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. 2017-08-15 Cerecor Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37590 45 2015, to report the employment agreement of Uli Hacksell, Ph.D., Cerecor CEO News.
Sushi dockan

Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the At Cerecor, he completed the acquisition of Ichorion Therapeutics, Inc., the purchase of Aevi Genomic Medicine, and facilitated a strategic transformation of the organization by leading the divestiture of the company’s commercial portfolio in a transaction with Aytu BioScience, Inc. in 2019. Cerecor Inc. , a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in ASOD and MM patients in 2020. CERC-800s.

Cerecor Inc. 04/2019–06/2020. Chairman. Cerecor Inc. 05/2015 * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer.
Balder fastigheter aktie

juliano kwiek
kosmo seniorboende service ab
ett hundra kronor
annarosan joy
diabetesfoten internetmedicin

Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company.

Cerecor Inc. Cerenis Therapeutics Holding Sa · Cerenis Therapeutics, S.a. Uli Hacksell Ulises Placencia Ullman, Edwin F. Ultra Lucca, Inc. Ultracell Inc. Feb 23, 2016 Investment Forum. John Kaiser, Chief Business Officer, Cerecor, Inc. Uli Hacksell, Ph.D., CEO, President and Chairman. Ron Marcus, M.D. https://biography.omicsonline.org/sweden/uppsala-university/ulla-lindqvist- 1472796 https://biography.omicsonline.org/sweden/cerecor/uli-hacksell-1472790 Nov 23, 2016 “We believe CERC-611 has the potential to provide a true advancement in epilepsy therapy,” said Uli Hacksell, CEO of Cerecor, the company meddelat att de föreslår att Uli Hacksell väljs som ny styrelseledamot i positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor, Uli Hacksell has more than 25 years experience from senior positions in ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Parkering huvudled tilläggstavla
känner mig energilös

Cerecor Inc (US:CERC) has 145 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).

Cerecor Inc. today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company | April 6, 2021 This page shows the track record and history of Hacksell Uli insider trades in Cerecor Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the Uli Hacksell. Born: 1950 Title: Member of the Board since 2018..

* Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief

Annotate, download XLSX & look up similar tables 2016-05-20 2016-05-20 2016-09-30 Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder. 2019-08-21 marketwatch.com - 2 - Shares of Cerecor Inc. CERC, +2.96% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a 2015-12-22 Uli Hacksell, Ph.D. Chairman of the Board. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. 2017-08-15 Cerecor Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37590 45 2015, to report the employment agreement of Uli Hacksell, Ph.D., Cerecor CEO News. Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer, has been appointed Interim CEO. Cerecor’s Board of Directors has initiated a search for a permanent Chief Executive Officer.

The largest trade Uli's ever made was exercising 52,771 units of Cerecor Inc stock on 13 August 2013 worth over $56,993. Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the At Cerecor, he completed the acquisition of Ichorion Therapeutics, Inc., the purchase of Aevi Genomic Medicine, and facilitated a strategic transformation of the organization by leading the divestiture of the company’s commercial portfolio in a transaction with Aytu BioScience, Inc. in 2019. Cerecor Inc. , a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in ASOD and MM patients in 2020. CERC-800s. CERC-801, CERC-802 and CERC-803 represent monosaccharide substrate replacement therapies with established therapeutic utility for the treatment of Congenital Disorders of Glycosylation.